The premenstrual syndrome revisited

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 130, Issue 1, 2007, Pages 4-17

  Campagne, Daniel M ^a   Campagne, Ghislaine ^b  

^a UNIVERSIDAD NACIONAL DE EDUCACIÓN A DISTANCIA   (Spain)

^b Clinica Bella Medica   (Spain)

Author keywords

Hormones; Luteal phase; Ovarian cycle; Premenstrual Dysphoric Disorder; Premenstrual Profile; Premenstrual syndrome; Psychometry

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BROMOCRIPTINE; BUSPIRONE; CALCIUM; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DESOGESTREL; DROSPIRENONE; FLUOXETINE; GESTAGEN; GONADORELIN AGONIST; HYPERICUM PERFORATUM EXTRACT; LEVONORGESTREL; LITHIUM; MAGNESIUM; MAPROTILINE; MONOAMINE OXIDASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PLACEBO; PRIMROSE OIL; PROGESTERONE; PYRIDOXINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SPIRONOLACTONE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIET; EVIDENCE BASED MEDICINE; FEEDING BEHAVIOR; FEMALE; HUMAN; HYSTERECTOMY; MENSTRUAL CYCLE; OVARIECTOMY; PHYTOTHERAPY; PREMENSTRUAL PROFILE; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PSYCHOMETRY; PSYCHOTHERAPY; REVIEW; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION; WELLBEING;

EID: 33845562080     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2006.06.020     Document Type: Review

References (119)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV-Text Revision). APA Washington; 1994/2002.
2. Rubinow D.R., and Schmidt P.J. Premenstrual syndrome: a review of endocrine studies. Endocrinologist 2 (1992) 47-56
3. Schmidt P.J., Purdy R.H., Moore Jr. P.H., Paul S.M., and Rubinow D.R. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J Clin Endocrinol Metab 79 (1994) 1256-1260
4. Lombardi I., Luisi S., Quirici B., et al. Adrenal response to adrenocorticotropic hormone stimulation in patients with premenstrual syndrome. Gynecol Endocrinol 18 February (2) (2004) 79-87
5. Roca C.A., Schmidt P.J., Altemus M., et al. Differential menstrual cycle regulation of hypothalamic-pituitary-adrenal axis in women with premenstrual syndrome and controls. J Clin Endocrin Metab 88 7 (2003) 3057-3063
6. Odber J., Cawood E.H., and Bancroft J. Salivary cortisol in women with and without perimenstrual mood changes. J Psychosom Res 45 December (6) (1998) 557-568
7. Mira M., Stewart P.M., and Abraham S.F. Vitamin and trace element status in premenstrual syndrome. Am J Clin Nutr 47 April (4) (1988) 636-644
8. Facchinetti F., Martignoni E., Petraglia F., Sances M.G., Nappi G., and Genazzani A.R. Premenstrual fall of plasma beta-endorphin in patients with premenstrual syndrome. Fertil Steril 47 April (4) (1987) 570-573
9. Tulenheimo A., Laatikainen T., and Salminen K. Plasma beta-endorphin immunoreactivity in premenstrual tension. Br J Obstet Gynaecol 94 January (1) (1987) 26-29
10. Chuong C.J., Coulam C.B., Bergstralh E.J., O'Fallon W.M., and Steinmetz G.I. Clinical trial of naltrexone in premenstrual syndrome. Obstet Gynecol 72 September (3 Pt 1) (1988) 332-336
11. Parry B.L., Javeed S., Laughlin G.A., Hauger R., and Clopton P. Cortisol circadian rhythms during the menstrual cycle and with sleep deprivation in premenstrual dysphoric disorder and normal control subjects. Biol Psychiatry 48 November (9) (2000) 920-931
12. Korzekwa M.I., Lamont J.A., and Steiner M. Late luteal phase dysphoric disorder and the thyroid axis revisited. J Clin Endocrinol Metab 81 June (6) (1996) 2280-2284
13. Joffe H., Cohen L.S., and Harlow B.L. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol 189 June (6) (2003) 1523-1530
14. Schmidt P.J., Nieman L.K., Grover G.N., Muller K.L., Merriam G.R., and Rubinow D.R. Lack of effect of induced menses on symptoms in women with premenstrual syndrome. N Engl J Med 324 April (17) (1991) 1174-1179
15. Wyatt K., Dimmock P., Jones P., et al. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ 323 October (2001) 776-780
16. Smith S.S., and Gong Q.H. Neurosteroid administration and withdrawal alter GABAA receptor kinetics in CA1 hippocampus of female rats. J Physiol 564 April (Pt 2) (2005) 421-436
17. Rapkin A.J., Morgan M., Goldman L., Brann D.W., Simone D., and Mahesh V.B. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 90 November (5) (1997) 709-714
18. Bao A.-M., Hestiantoro A., Van Someren E.J.W., Swaab D.F., and Zhou J.-N. Colocalization of corticotropin-releasing hormone and oestrogen receptor-α in tehe paraventricular nucleus of the hypothalamus in mood disorders. Brain 128 Jun (Pt 6) (2005) 1301-1313
19. Lund T.D., Rovis T., Chung W.C.J., and Handa R.J. Novel actions of estrogen receptor-β on anxiety-related behaviours. Endocrinology 146 2 (2005) 797-807
20. Campagne D.M. La gradación del efecto placebo. Un estudio N = 1, doble ciego, con Belladona homeopática 30 C. Psiquis 4 (2002) 148-154
21. Gelder M., Gath D., and Mayou R. Concise Oxtord textbook of psychiatry (1998), Oxford University Press, Oxford p. 242
22. Watson N.R., Studd J.W.W., Savas M., et al. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet ii (1989) 730-732
23. Rubinow D.R., and Roy-Byrne P. Premenstrual syndromes: overview from a methodologic perspective. Am J Psychiatry 141 February (2) (1984) 163-172
24. Brooks J., Ruble D., and Clark A. College women's attitudes and expectations concerning menstrual-related changes. Psychosom Med 39 September-October (5) (1977) 288-298
25. Haywood A., Slade P., and King H. Assessing the assessment measures for menstrual cycle symptoms: a guide for researchers and clinincias. J Psychosom Res 52 April (4) (2002) 223-237
26. Ross C., Coleman G., and Stojanovska C. Factor structure of the modified Moos Menstrual Distress Questionnaire: assessment of prospecytively reported follicular, menstrual and premenstrual symptomatology. J Psychosom Obstet Gynaecol 24 September (3) (2003) 163-174
27. Ruble D.N. Premenstrual symptoms: a reinterpretation. Science 197 July (4300) (1977) 291-292
28. Halbreich U., and Endicott J. Classification of premenstrual syndromes. In: Friedman R. (Ed). Behaviour and the menstrual cycle (1982), Marcel Dekker, New York
29. Vila J., and Beech H.R. Premenstrual symptomatology: an interaction hypothesis. Br J Soc Clin Psychol 19 February (1) (1980) 73-80
30. AuBuchon P.G., and Calhoun K.S. Menstrual cycle symptomatology: the role of social expectancy and experimental demand characteristics. Psychosom Med 47 January-February (1) (1985) 35-45
31. Olasov B., and Jackson J. Effects of expectancies on women's reports of moods during the menstrual cycle. Psychosom Med 49 (1987) 65-77
32. Eisenberg L. The subjective in medicine. Perspect Biol Med 27 (1983) 48
33. Gallant S.J., Popiel D.A., Hoffman D.M., Chakraborty P.K., and Hamilton J. Using daily ratings to confirm premenstrual syndrome/late luteal phase dysphoric disorder. Psychosom Med 54 March-April (2) (1992) 149-181
34. Angst J., Sellaro R., Merikangas K.R., and Endicott J. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 104 August (2) (2001) 110-116
35. Smith M.J., Schmidt P.J., and Rubinow D.R. Operationalizing DSM-IV criteria for PMDD: selecting symptomatic and asymptomatic cycles for research. J Psychiatr Res 37 January-February (1) (2003) 75-83
36. Johannes C., Woods J.C., Crawford S., Cochran H., Tran D., and Schuth B. Electronic versus paper instruments for daily data collection. Ann Epidemiol 10 October (7) (2000) 457
37. Gise L.H., Lebovits A.H., Paddison P.L., and Strain J.J. Issues in the identification of prmenstrual syndromes. J Nerv Ment Dis 178 April (4) (1990) 228-234
38. Kessel B. Premenstrual sydrome. Advances in diagnosis and treatment. Obstet Gynecol Clin North Am 27 (2000) 625-639
39. Steiner M., Haskett R., and Carroll B. Premenstrual tension syndrome: the development of research diagnostic criteria and new rating scales. Acta Psychiatr Scand 62 (1980) 177-190
40. Campagne D.M. Detectar la depresión antes, durante y después de la gestación con el perfil anímico del embarazo. Prog Obstet Ginecol 47 1 (2004) 27-35
41. Parry B.L. Psychobiology of premenstrual dysphoric disorder. Semin Reprod Endocrinol 15 February (1) (1997) 55-68
42. Renckens C.N.M. Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Hum Reprod 20 April (4) (2005) 1113-1114
43. Abraham S., Luscombe G., and Soo I. Oral contraception and cyclic changes in premenstrual and menstrual experiences. J Psychosom Obstet Gynaecol 24 September (3) (2003) 185-193
44. Winkler U.H., Ferguson H., and Mulders J.A. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 μg ethinylestradiol. Contraception 69 June (6) (2004) 469-476
45. Sillem M., Schneidereit R., Heithecker R., and Mueck A.O. Use of an oral contraceptive containing drospirenone in an extended regimen. Eur J Contracept Reprod Health Care 8 September (3) (2003) 162-169
46. Joffe H., Cohen L.S., and Harlow B.L. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol 189 December (6) (2003) 1523-1530
47. Yonkers K.A., Brown C., Pearlstein T.B., Foegh M., Sampson-Landers C., and Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obst Gynecol 106 (2005) 492-501
48. Vellacott I.D., Shroff N.E., Pearce M.Y., Stratford M.E., and Akbar F.A. A double-blind, placebo-controlled evaluation of spironolactone in the premenstrual syndrome. Curr Med Res Opin 10 7 (1987) 450-456
49. Burnet R.B., Radden H.S., Easterbrook E.G., and McKinnon R.A. Premenstrual syndrome and spironolactone. Aust N Z J Obstet Gynaecol 31 November (4) (1991) 366-368
50. Wang H., Hammerback S., Lindhe B.A., and Backstrom T. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand 74 November (10) (1995) 803-808
51. Khoo S.K., Munro C., and Battistutta D. Evening primrose oil and treatment of premenstrual syndrome. Med J Aust 153 August (4) (1990) 189-192
52. Collins A., Cerin A., Coleman G., and Landgren B.-M. Essential fatty acids in the treatment of premenstrual syndrome. Obstet Gynecol 81 (1993) 93-98
53. Budeiri D., Li Wan Po A., and Dornan J.C. Is evening primrose oil of value in the treatment of premenstrual syndrome?. Contr Clin Trials 17 1 (1996) 60-68
54. Puolakka J., Makarainen L., Viinikka L., and Ylikorkola O. Biochemical and clinical effects of treating the premenstrual syndrome with prostaglandin synthesis precursors. J Reprod Med 30 March (3) (1985) 149-153
55. Mira M., McNeil D., Fraser I.S., Vizzard J., and Abraham S. Mefenamic acid in the treatment of premenstrual syndrome. Obstet Gynecol 68 September (3) (1986) 395-398
56. a ed. (1984), Yearbook Medical Publishers, Inc., Chicago
57. Sampson G.A. Premenstrual syndrome: a double-blind controlled trial of progesterone and placebo. Br J Psychiatry 135 September (1979) 209-215
58. Van der Meer Y.G., Benedek-Jaszmann L.J., and Van Loenen A.C. Effects of high-dose progesterone on the premenstrual syndrome: a double-blind cross-over trial. J Psychosom Obstet Gynaecol 2 (1983) 220-222
59. Andersch B., and Hahn L. Progesterone treatment of premenstrual tension-a double blind study. J Psychosom Res 29 5 (1985) 489-493
60. Richter M.A., Haltvick R., and Shapiro S.S. Progesterone treatment of premenstrual syndrome. Curr Ther Res 36 (1984) 850
61. Maddocks S., Hahn P., Moller F., and Reid R.L. A double-blind placebo-controlled trial of progesterone vaginal suppositories in the treatment of premenstrual syndrome. Am J Obstet Gynecol 154 March (3) (1986) 573-581
62. Freeman E., Rickels K., Sondheimer S.J., and Polansky M. Ineffectiveness of progesterone suppository treatment for premenstrual syndrome. JAMA 264 July (3) (1990) 349-353
63. Freeman E.W., Richels K., Sondheimer S.J., and Polansky M. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 274 July (1) (1995) 51-57
64. Dennerstein L., Spencer-Gardner C., Gotts G., Brown J.B., Smith M.A., and Burrows G.D. Progesterone and the premenstrual syndrome: a double blind cross-over trial. Br Med J (Clin Res Ed) 290 June (6482) (1985) 1617-1621
65. Casson P., Hahn P.M., Van Vugt D.A., and Reid R.L. Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am J Obstet Gynecol 162 January (1) (1990) 99-105
66. Cronje WH, Vashisht A, Studd JW. Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Hum Reprod 2004;19 (9):2152-5 [Epub June 30, 2004].
67. Casper R.F., and Hearn M.T. The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. Am J Obstet Gynecol 162 January (1) (1990) 105-109
68. Rapkin A. A review of treatment of premenstrual syndrome and prementrual dysphoric disorder. Psychoneuroendocrinology 28 August (Suppl. 3) (2003) 39-53
69. Mortola J.F., Girton L., and Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab 72 February (2) (1991) 252A-1252A
70. Hussain S.Y., Massil J.H., Matta W.H., Shaw R.W., and O'Brien P.M. Buserelin in premenstrual syndrome. Gynecol Endocrinol 6 March (1) (1992) 57-64
71. Wyatt K.M., Dimmock P.W., Ismail K.M., Jones P.W., and O'Brien P.M. The effectiveness of GnRHa with and without 'add-back' therapy in treating premenstrual syndrome: a meta analysis. BJOG 111 June (6) (2004) 585-593
72. Thys-Jacobs S., Starkey P., Bernstein D., and Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Am J Obstet Gynecol 179 August (2) (1998) 444-452
73. Bertone-Johnson E.R., Hankinson S.E., Bendich A., Johnson S.R., Willett W.C., and Manson J.E. Calcium and vitamin D intake and risk of incident premenstrual syndrome. Arch Intern Med 165 (2005) 1246-1252
74. Khine K., Rosenstein D.L., Elin R.J., Niemela J.E., Schmidt P.J., and Rubinow D.R. Magnesium (Mg) retention and mood effects after intravenous Mg infusion in premenstrual dysphoric disorder. Biol Psychiatry 59 Feb (4) (2006) 327-333
75. De Souza M.C., Walker A.F., Robinson P.A., and Bolland K. A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms: a randomized, double-blind, crossover study. J Womens Health Gend Based Med 9 March (2) (2000) 131-139
76. Stone A.B., Pearlstein T.B., and Brown W.A. Fluoxetine in the treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 52 July (7) (1991) 290-293
77. Wood S.H., Mortola J.F., Chan Y.F., Moossazadeh F., and Yen S.S. Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. Obstet Gynecol 80 September (3 Pt 1) (1992) 339-344
78. Menkes D.B., Taghavi E., Mason P.A., Spears G.F., and Howard R.C. Fluoxetine treatment of severe premenstrual syndrome. BMJ 305 August (6849) (1992) 346-347
79. Sundblad C., Hedberg M.A., and Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology 9 September (2) (1993) 133-145
80. Eriksson E., Hedberg M.A., Andersch B., and Sundblad C. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology 12 April (2) (1995) 167-176
81. Steiner M., Steinberg S., Stewart D., et al. Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med 332 June (23) (1995) 1529-1534
82. Yonkers K.A., Halbreich U., Freeman E., et al., for the Sertraline Premenstrual Dysphoric Colloborative Study Group. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. JAMA 278 September (12) (1997) 983-988
83. Eriksson E. Serotonin re-uptake inhibitors for the treatment of premenstrual dysphoria. Int Clin Psychopharmacol 14 Suppl. 2 (1997) S27-S33
84. Pearlstein T.B., Stone A.B., Lund S.A., Scheft H., Zlotnick C., and Brown W.A. Comparison of fluoxetine, bupropion and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 17 August (4) (1997) 261-266
85. Freeman E.W. Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder. CNS Drugs 18 7 (2004) 453-468
86. Freeman E.W., Rickels K., Sondheimer S.J., Polansky M., and Xiao S. Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Am J Psychiatry 161 February (2) (2004) 343-351
87. Steiner M., Hirschberg A.L., Bergeron R., Holland F., Gee M.D., and Van Erp E. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Am J Obstet Gynecol 193 August (2) (2005) 352-360
88. Freeman E.W., and Sondheimer S.J. Premenstrual dysphoric disorder: recognition and treatment. Prim Care Companion J Clin Psychiatry 5 February (1) (2003) 30-39
89. Blum I., Lerman M., Misrachi I., et al. Lack of plasma norepinephrine cyclicity, increased estradiol during the follicular phase, and of progesterone and gonadotrophins at ovulation in women with premenstrual syndrome. Neuropsychobiology 50 1 (2004) 10-15
90. Huang K.L., and Tsai S.J. StJohn's wort (Hypericum perforatum) as a treatment for premenstrual dysphoric disorder: case report. In J Psychiatr Med 33 3 (2003) 295-297
91. Smith S., Rinehart J.S., Ruddock V.E., and Schiff I. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet Gynecol 70 July (1) (1987) 37-43
92. Harrison W.M., Endicott J., and Nee J. Treatment of premenstrual dysphoria with alprazolam. Arch Gen Psychiatry 47 3 (1990) 270-275
93. West C.P., and Hillier H. Ovarian suppression with the gonadotrophin-releasing hormone agonist goserelin (Zoladex) in management of the premenstrual tension syndrome. Hum Reprod 9 June (6) (1994) 1058-1063
94. Moynihan R. Controversial disease dropped from Prozac product information. BMJ 328 February (2004) 365
95. Minton J.P., Foecking M.K., and Webster D.J.T. Caffeine, cyclic nucleotides and breast disease. Surgery 86 (1979) 105
96. Bryant M., Cassidy A., Hill C., Powell J., Talbot D., and Dye L. Effect of consumption of soy isoflavones on behavioural, somati and affective symptoms in women with premenstrual syndrome. Br J Nutr 93 5 (2005) 731-739
97. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomized, placebo controlled study. BMJ 322 (2001) 134-137
98. Daniele C., Thompson Coon J., Pittler M.H., and Ernst E. Vitex agnus castus: a systematic review of adverse events. Druf Saf 28 January (4) (2005) 319-332
99. Atmaca M., Kumru S., and Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol 18 April (3) (2003) 191-195
100. The American College of Obstetricians and Gynecologists. ACOG practice bulletin, Number 15, April 2000.
101. Bailey J.W., and Cohen L.S. Prevalence of mood and anxiety disorders in women who seek treatment for premenstrual syndrome. J Womens Health Gend Based Med 8 November (9) (1999) 1181-1184
102. Keye Jr. W.R., and Trunnell E.P. A biopsychosocial model of premenstrual syndrome. Int J Fertil 31 September-October (4) (1986) 259-262
103. Keye Jr. W.R. Premenstrual syndrome. Seven steps in management. Postgrad Med 83 February (3) (1988) 167-173
104. Woods N.F., Mitchell E.S., and Lentz M.J. Social pathways to premenstrual symptoms. Res Nurs Health 18 June (3) (1995) 225-237
105. Pérez R., Ferreres A., Gadea M., González E., Hernández A., and Navarro N. Efectos de la información acerca del ciclo menstrual sobre las actitudes hacia la menstruación. Psicothema 7 2 (1995) 297-308
106. Kirsch J.R., and Geer J.H. Skin conductance and heart rate in women with premenstrual syndrome. Psychosom Med 50 (1998) 175-182
107. Elliot T.R. Problem-solving appraisal, oral contraceptive use, and menstrual pain. J Appl Soc Psychol 22 3 (1992) 286-297
108. Schmidt P.J., Grover G.N., Hoban M., and Rubinow D.R. State-dependent alterations in the perception of life events in menstrual-related mood disorders. Am J Psychiatry 147 2 (1990) 230-234
109. Ussher J.M., and Wilding J.M. Performance and state changes during the menstrual cycle, conceptualized within a broad band testing framework. Social Sci Med 32 5 (1991) 525-534
110. Morgan M., Rapkin A.J., D'Elia L., Reading A., and Goldman L. Cognitive funtioning in premenstrual syndrome. Obstet Gynecol 88 December (6) (1996) 961-966
111. Van Tilburg M.A., Becht M.C., and Vingerhoets A.J. Sel-reported crying during the menstrual cycle: sign of discomfort and emotional turmoil or erroneous beliefs?. J Psychosom Obstet Gynaecol 24 December (4) (2003) 247-255
112. Christensen A.P., and Oei T.P. The efficacy of cognitive behaviour therapy in treating premenstrual dysphoric changes. J Affect Disord 33 January (1) (1995) 57-63
113. Blake F., Salkovskis P., Gath D., Day A., and Garrod A. Cognitive therapy for premenstrual syndrome: a controlled trial. J Psychosom Res 45 October (4) (1998) 307-318
114. Hunter M.S., Essher J.M., Cariss M., Browne S., Jelley R., and Katz M. Medical (fluoxetine) and psychological (cognitive-behavioural therapy) treatment for premenstrual dysphoric disorder: a study of treatment processes. J Psychosom Res 53 September (3) (2002) 811-817
115. Hunter M.S., Ussher J.M., Browne S.J., Cariss M., Jelley R., and Katz M. A randomized comparison of psychological (cognitive behaviour therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 23 September (3) (2002) 193-199
116. Dickerson L.M., Mazyck P.J., and Hunter M.H. Premenstrual syndrome. Am Fam Physician 67 April (8) (2003) 1743-1752
117. Lovick T.A. Plasticity of GABAA receptor subunit expression during the oestrous cycle - implications for premenstrual syndrome in women. Exp Physiol 91 Jul (4) (2006) 655-660
118. Halbreich U., O'brien P.S., Eriksson E., Backstrom T., Yonkers K.A., and Freeman E.W. Are thee differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder?. CNS Drugs 20 Jan (7) (2006) 523-547
119. Kim H.W., Kwon M.K., Kim N.S., and Reame N.E. Intake of dietary soy isoflavones in relation to perimenstrual symptoms of Korean women living in the USA. Nurs Health Sci 8 Jun (2) (2006) 108-113